Harnessing Microbial Recognition and Host Defense Responses To Fight Cancer
Manhattan BioSolutions is an emerging biotech company focused on the development of biologic therapies that target microbial recognition and host-defense pathways for the treatment of advanced, metastatic cancers. We develop innovative tumor-targeted agents that selectively destroy cancer cells while sparing healthy tissues
In the News
Scientific Platforms
Biologics
Developing novel biologics – mAbs & ADCs that target immuno-regulatory receptors overexpressed in tumors. The ADCs are designed to selectively eliminate cancer cells via multiple immune-mediated mechanisms
Synthetic Microbes
The sMIST (Synthetic Microbial Immune Stimulators) platform is based on genetically engineered microbes – “living drugs” that target mutated tumor antigens to induce innate and tumor-specific adaptive immunity
Get in touch !
If you are interested in exploring innate immunity and its translation into human therapies, or if your technology could advance the science, please contact us at ir@manhattanbiosolutions.com